Partner Content Partner Content Hemophilia Treatment Market will witness 5%+ CAGR up to 2025 Hemophilia Treatment Market will exceed $14bn by 2024
News Novartis halts CAR-T trials after patient deaths Novartis stops eight trials of CAR-T rap-cel in autoimmune diseases after three deaths, with BMS also halting studies of zola-cel as a precaution.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
